Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
5 search results for:

LOXO-292 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 08-06-2018 | RET inhibitors | ASCO 2018 | Article

    LOXO-292 demonstrates ‘robust’ efficacy against RET-altered tumors

    The selective RET inhibitor LOXO-292 has activity against tumors harboring a range of RET alterations, according to findings from the first-in-human LIBRETTO-001 trial.

    Published in:
    ASCO Annual Meeting 2018; Chicago, Illinois, USA
  2. 15-05-2020 | FDA | News | Article
    approvalsWatch

    Selpercatinib receives FDA nod

    Read more about this approval here

    Author:
    Shreeya Nanda
  3. 30-04-2018 | RET inhibitors | News | Article

    More evidence for selective RET inhibition in RET-altered cancers

    A report of two patients with advanced tumors harboring alterations in the RET gene who responded to treatment with the selective inhibitor LOXO-292 highlights that the clinical actionability of RET mutations, say researchers.

    Published in:
    Ann Oncol 2018; Advance online publication

  4. LIBRETTO-001 trial

    LIBRETTO-001 is phase I/II study of the RET inhibitor LOXO-292 in patients with advanced RET-altered cancers.

  5. 12-09-2019 | Non-small-cell lung cancer | News | Article

    LIBRETTO-001: Selpercatinib achieves high ORRs in RET fusion-positive NSCLC

    By contrast, selpercatinib – previously known as LOXO-292 – is a selective RET inhibitor that was designed to be active against resistance mutations and cross the blood–brain barrier, Drilon stated.

    Published in:
    IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.